341 related articles for article (PubMed ID: 20589670)
1. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
[TBL] [Abstract][Full Text] [Related]
2. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture.
Genzel Y; Fischer M; Reichl U
Vaccine; 2006 Apr; 24(16):3261-72. PubMed ID: 16472544
[TBL] [Abstract][Full Text] [Related]
3. Use of MDCK cells for production of live attenuated influenza vaccine.
Liu J; Shi X; Schwartz R; Kemble G
Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
[TBL] [Abstract][Full Text] [Related]
4. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media.
Genzel Y; Olmer RM; Schäfer B; Reichl U
Vaccine; 2006 Aug; 24(35-36):6074-87. PubMed ID: 16781022
[TBL] [Abstract][Full Text] [Related]
5. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
[TBL] [Abstract][Full Text] [Related]
6. Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor.
Sun B; Yu X; Kong W; Sun S; Yang P; Zhu C; Zhang H; Wu Y; Chen Y; Shi Y; Zhang X; Jiang C
Appl Microbiol Biotechnol; 2013 Feb; 97(3):1063-70. PubMed ID: 22945265
[TBL] [Abstract][Full Text] [Related]
7. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells.
Hussain AI; Cordeiro M; Sevilla E; Liu J
Vaccine; 2010 May; 28(22):3848-55. PubMed ID: 20307595
[TBL] [Abstract][Full Text] [Related]
8. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
[TBL] [Abstract][Full Text] [Related]
9. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D
Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model.
Nerome K; Kumihashi H; Nerome R; Hiromoto Y; Yokota Y; Ueda R; Omoe K; Chiba M
Dev Biol Stand; 1999; 98():53-63; discussion 73-4. PubMed ID: 10494959
[TBL] [Abstract][Full Text] [Related]
11. [Development of a novel influenza vaccine derived from a continuous cell line].
Kistner O; Barrett N; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
ALTEX; 2001; 18(1):50-4. PubMed ID: 11248852
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
Heldens J; Hulskotte E; Voeten T; Breedveld B; Verweij P; van Duijnhoven W; Rudenko L; van Damme P; van den Bosch H
Vaccine; 2014 Sep; 32(39):5118-24. PubMed ID: 24858566
[TBL] [Abstract][Full Text] [Related]
13. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
Palker T; Kiseleva I; Johnston K; Su Q; Toner T; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Wlochowski J; Monteiro J; Kraiouchkine N; DiStefano D; Rudenko L; Shaw A; Youil R
Virus Res; 2004 Oct; 105(2):183-94. PubMed ID: 15351492
[TBL] [Abstract][Full Text] [Related]
14. Continuous cell lines as a production system for influenza vaccines.
Genzel Y; Reichl U
Expert Rev Vaccines; 2009 Dec; 8(12):1681-92. PubMed ID: 19943763
[TBL] [Abstract][Full Text] [Related]
15. Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production-Flow cytometry and mathematical modeling.
Schulze-Horsel J; Schulze M; Agalaridis G; Genzel Y; Reichl U
Vaccine; 2009 May; 27(20):2712-22. PubMed ID: 19428884
[TBL] [Abstract][Full Text] [Related]
16. Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin.
Schwarzer J; Rapp E; Hennig R; Genzel Y; Jordan I; Sandig V; Reichl U
Vaccine; 2009 Jul; 27(32):4325-36. PubMed ID: 19410619
[TBL] [Abstract][Full Text] [Related]
17. Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor.
Chu C; Lugovtsev V; Lewis A; Betenbaugh M; Shiloach J
Vaccine; 2010 Oct; 28(44):7193-201. PubMed ID: 20800699
[TBL] [Abstract][Full Text] [Related]
18. Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness.
Kim EH; Kwon HI; Park SJ; Kim YI; Si YJ; Lee IW; Kim SM; Kim SI; Ahn DH; Choi YK
J Microbiol Biotechnol; 2018 Jun; 28(6):997-1006. PubMed ID: 29642288
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
[TBL] [Abstract][Full Text] [Related]
20. A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor.
Lohr V; Genzel Y; Behrendt I; Scharfenberg K; Reichl U
Vaccine; 2010 Aug; 28(38):6256-64. PubMed ID: 20638458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]